Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...

Faro Health Inc., the leading AI-powered platform for data-driven clinical protocol design, today announced it has partnered with Recursion (NASDAQ: RXRX) to accelerate and optimize clinical protocol ...

NULISA employs a sequential immunocomplex capture and release technique to improve the sensitivity of traditional proximity ...

Regenxbio, a prolific developer of gene therapy technology, will hand Japan’s Nippon Shinyaku certain rights to two ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...

On the first day of the J.P. Morgan Healthcare Conference, drug executives talked M&A, but also sized up the prospects of ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...